At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Capecitabine Rapidly Disintegrating Tablets and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas
In Brief
A Phase 2 clinical trial evaluating Capecitabine and Radiation therapy for Brainstem Glioma. Completed, enrolled 45 participants across 8 sites.
Detailed Summary
This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBrainstem Glioma
CountriesUnited States
CollaboratorsPediatric Brain Tumor Consortium
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2007
First PostedMay 2010
Primary CompletionJan 2013
Study CompletionApr 2013
TodayJul 2026
First PostedMay 6, 2010
Enrollment StartMay 1, 2007
Primary CompletionJan 1, 2013
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 16.2 years ago
Interventions
Capecitabinedrug
Capecitabine was supplied as film-coated tablets.
Radiation therapyradiation
Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.